• 1. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 2. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 3. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227

Professional Introduction to 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile (CAS No: 1221791-93-0)

8-bromoimidazo[1,2-a]pyridine-6-carbonitrile is a highly significant compound in the field of pharmaceutical chemistry, renowned for its versatile applications in drug discovery and medicinal research. This heterocyclic compound, characterized by its unique structural framework, has garnered considerable attention due to its potential in developing novel therapeutic agents. The presence of both bromo and nitrile functional groups in its molecular structure enhances its reactivity, making it a valuable intermediate in synthetic chemistry.

The chemical structure of 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile consists of an imidazo[1,2-a]pyridine core substituted with a bromine atom at the 8-position and a nitrile group at the 6-position. This arrangement not only imparts distinct electronic properties but also facilitates various chemical transformations, which are crucial for medicinal chemistry applications. The compound’s molecular formula, C₈H₃BN₂O, reflects its composition and highlights its potential as a building block in the synthesis of more complex molecules.

In recent years, the pharmaceutical industry has witnessed a surge in the exploration of imidazo[1,2-a]pyridine derivatives due to their demonstrated efficacy in various biological assays. These derivatives have been shown to exhibit inhibitory activity against a range of enzymes and receptors, making them promising candidates for the treatment of infectious diseases, cancer, and inflammatory disorders. The bromo substituent in 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile particularly enhances its utility as a synthetic precursor, enabling further functionalization through cross-coupling reactions such as Suzuki-Miyaura and Buchwald-Hartwig couplings.

The nitrile group at the 6-position of the molecule contributes to its reactivity by participating in nucleophilic addition reactions. This feature has been exploited in various synthetic strategies to introduce additional functional groups or to construct more elaborate molecular architectures. Researchers have leveraged these properties to develop novel scaffolds that exhibit improved pharmacokinetic profiles and enhanced binding affinity to biological targets. For instance, recent studies have demonstrated the utility of this compound in generating potent inhibitors of kinases and other enzymes involved in signal transduction pathways.

One of the most compelling aspects of 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile is its role in the development of antiviral agents. The imidazo[1,2-a]pyridine core is a known pharmacophore that interacts with viral proteins essential for replication and propagation. By incorporating bromo and nitrile groups into this framework, chemists have been able to fine-tune the electronic and steric properties of the molecule to optimize its antiviral activity. Preliminary findings suggest that derivatives of this compound exhibit significant inhibitory effects against certain viral strains, offering hope for new therapeutic interventions.

The synthesis of 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile involves multi-step organic transformations that highlight the compound’s synthetic versatility. Key steps typically include cyclization reactions to form the imidazo[1,2-a]pyridine ring system followed by selective bromination and cyanation at designated positions. Advances in catalytic methods have further streamlined these processes, allowing for higher yields and improved scalability. These synthetic advancements have made it feasible to produce sufficient quantities of the compound for both academic research and industrial applications.

The pharmacological evaluation of 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile has revealed several promising characteristics that make it an attractive candidate for drug development. In vitro studies have shown that this compound exhibits moderate potency against various disease-related targets, including enzymes overexpressed in cancer cells and viral proteases. Additionally, its favorable solubility profile and stability under physiological conditions enhance its potential as a lead compound for further optimization.

The future prospects of this compound are further bolstered by ongoing research efforts aimed at expanding its therapeutic applications. Collaborative studies between chemists and biologists are exploring novel derivatives that may exhibit enhanced efficacy or reduced toxicity compared to existing treatments. Computational modeling techniques are also being employed to predict binding interactions between 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile and biological targets, providing insights into structure-activity relationships that can guide rational drug design.

In conclusion, 8-bromoimidazo[1,2-a]pyridine-6-carbonitrile (CAS No: 1221791-93-0) represents a cornerstone in modern pharmaceutical chemistry due to its unique structural features and broad applicability. Its role as a versatile intermediate has enabled the synthesis of numerous bioactive molecules with potential therapeutic value. As research continues to uncover new applications for this compound, it is poised to remain a critical tool in the quest for innovative treatments across multiple disease domains.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)